Amendments to the Claims:

Please amend claims 1 to 19 as set forth hereinafter, including the cancellation of claims 6 to 11. Please add new claims 20 to 26

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) Peptides of the AT_1 receptor, comprising 5 to ~~30amino~~ 30 amino acids as well as their variants, which can form an epitope and bind auto-antibodies occurring in preeclampsia and malign hypertension.

2. (Currently Amended) Peptides according to Claim 1, wherein they comprise ~~SEQ ID no. 1 AFHYESQ~~ SEQ ID NO: 1 (AFHYESQ) or contain this sequence in an identical or slightly modified form.

3. (Currently Amended) Peptides according to Claim 1, wherein they comprise at least one of the amino acid sequences AVHYQSN (SEQ ID NO: 2), SHFYQTR (SEQ ID NO: 3), GYYFDTN (SEQ ID NO: 4) or ENTNIT (SEQ ID NO: 5) or contain at least one of these sequences in an identical or slightly modified form.

4. (Previously Presented) Antibodies aimed against the epitope of the AT_1 receptor, wherein they recognise the peptides according to claim 1.

5. (Currently Amended) Antibodies according to Claim 4, wherein they recognise the peptides of SEQ ID NO: 1 ~~no. 1~~ (AFHYESQ) or peptides with the amino acid sequence (SEQ ID NO: 2), SHFYQTR (SEQ ID NO: 3), GYYFDTN (SEQ ID NO: 4) or ENTNIT (SEQ ID NO: 5).

6. – 11. (Cancelled)

12. (Previously Presented) Method for binding and elimination of the pathological, functionally active autoantibodies according to claim 4 in body fluids, in particular blood, by use of inspecific adsorber molecules chosen from the group consisting of protein A, protein G, antihuman immunoglobulin as well as overall immunoglobulin binding ligands chosen from the group consisting of L-tryptophane and peptides.

13. (Previously Presented) A method for the immunisation of mammals for the purpose of obtaining polyclonal and monoclonal antibodies, comprising using peptides at least containing at least one of the amino acid sequences according to claim 1.

14. (Currently Amended) ~~Use of~~ A method for immunisation of mammals for the purpose of obtaining antiidiotypical antibodies, comprising using antibodies aimed against the amino acid sequences according to claim 1.

15. (Previously Presented) Antigenic agent for detection of preeclampsia and malign hypertension, wherein it contains at least one peptide according to claim 1.

16. (Previously Presented) Immunogenic agent, wherein it contains at least one peptide according to claim 1, which induces the production of antibodies capable of recognising auto-antigens in preeclampsia or malign hypertension.

17. (Previously Presented) Test kit to determine anti- AT_1 receptor antibodies for proof of preeclampsia or malign hypertension, containing at least one peptide according to claim 1.

18. (Previously Presented) Method for detecting anti- AT_1 receptor antibodies in biological fluids, wherein the sample to be examined is brought into contact with at least one peptide of claim 1 or with a combination of these peptides with a carrier material under conditions permitting an antigen-antibody reaction and rendering proof by means of physical or chemical methods.

19. (Currently Amended) A method for production of therapeutic agents against preeclampsia or malign hypertension~~. Comprising~~ comprising using the peptides according to claim 1.

20. (New) A method for binding auto-antibodies comprising:

providing isolated peptides of an A_1 receptor comprising 5 to 30 amino acids, wherein said peptides bind auto-antibodies occurring in patients with preeclampsia and malign hypertension,
contacting said peptides with a body fluid, and
binding said auto-antibodies in said body fluid via said peptides.

21. (New) The method of claim 20, wherein said peptides are soluble or bound to a solid phase and wherein the method further comprises a direct or indirect detection of auto-antibodies in the body fluid.

22. (New) The method of claim 20, wherein said peptides comprise at least one of amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5.

23. (New) The method of claim 22, wherein said peptides consist essentially of at least one of amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5.

24. (New) The method of claim 20, wherein the peptides are bound to a solid phase and wherein the method further comprises neutralizing said auto-antibodies via said peptides.

25. (New) The method of claim 24, wherein said body fluid is maternal blood.

26. (New) The method of claim 24, wherein said solid phase is part of a column.